Lung Cancer
Conditions
Brief summary
The purpose of this project is to investigate if PET/MR imaging improves the accuracy in visualization and characterization of lung cancer disease, compared to PET/CT.
Detailed description
Lung cancer is the most frequent cancer type and the leading cause of cancer-related death worldwide. Positron emission tomography (PET) coupled with computed tomography (CT) is the standard of care for visualization and staging of lung cancer. Recent clinical introduction of hybrid PET and magnetic resonance (MR) imaging systems has shown potential to improve tumor imaging beyond the limits of PET/CT. However, knowledge about the clinical impact of this new hybrid modality is still limited. This project aims to investigate how PET/MR may improve the diagnosis and treatment of lung cancer disease, compared to PET/CT: PET/MR may allow early detection of brain and liver metastases, which strongly affects treatment outcome and survival; predictive models based on machine learning may combine image derived biomarkers from PET/MR, histology and health record data, to automatically visualize and characterize the tumor, facilitating computer aided diagnosis and personalized radiotherapy treatment.
Interventions
DIAGNOSTIC_TESTPET/MR
The included patients are imaged with PET/MR as part of the research protocol.
DIAGNOSTIC_TESTPET/CT
The included patients are imaged with PET/CT as part of normal clinical routine.
Sponsors
University Hospital of North Norway
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Referred to clinical PET/CT examination for investigation of lung disease.
Exclusion criteria
* Blood glucose level \>8.3 mmol/l * MR incompatible objects, e.g. metal implants, inside the body * Intolerance to gadolinium-based contrast agents, e.g. severe renal disease (GFR\<30). * Unable to give written consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity and specificity of PET/MR vs. clinical routine PET/CT | 1-2 weeks after the initial inclusion. | Sensitivity and specificity of PET/MR scans will be compared with in clinical routine PET/CT examinations for lung cancer disease feature prediction. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Prediction of treatment response and progression-free survival | 1 year after inclusion. | We will investigate which PET/MR or PET/CT features are best suited as an imaging biomarker for treatment response evaluation and for progression-free survival 1 year after inclusion. |
Countries
Norway
Outcome results
None listed